USPTO serial 79182715
BIOSE
Reviewed by CopyMark Law Group
Reg. 5056931Status 706Renewal
- Filing date
- Status date
- Registration date
- Oct 11, 2016
- Examiner
- NEVILLE, BRIAN
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BIOSE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $850
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William S. Fultz
William S. Fultz Womble Bond Dickinson (US) LLP555 Fayetteville Street, Suite 1100Raleigh, NC 27601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical products made with the microbiota, namely, bacteria, probiotics and tribiotics for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; chemical or biological pharmaceutical preparations for pharmaceutical, medical and sanitary purposes, namely, microbiota, bacteria, probiotics and tribiotics for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; sanitary and medical preparations, namely, bacteria for use in the composition of biological pharmaceuticals for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; biological or chemical preparations for pharmaceutical, medical use, toilet, namely, probiotics, tribiotics in capsules, capsules and sachets for treating or preventing the gastroenterological disease, gyncological, ear, nose and throat, dermatological, allergic, immune or inflammatory, diseases associated with an imbalance in the vaginal or intestinal flora, flatulence, diarrhea, abdominal pain, spasms, or for improving regulation of intestinal transit; vaginal capsules for treating gynecological diseases; preparations for medical use, namely, antifungals, antimycotics, antiflatulent agents, antidiarrheic agents, antispasmodics, antiinflammatories or antibiotics; disinfectants for hygiene care of patients suffering from gastroenterological diseases, imbalance of the intestinal flora, gynecological diseases, imbalance of the vaginal flora; nutritional supplements, namely, food beverages, bars and meal replacement substances adapted for medical use, dietetic purposes, treating or preventing gynecological disorders, gastroenterological, intestinal disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat; nutritional supplements, namely, meal replacement foods, beverages, bars made from a combination of probiotics, minerals and/or vitamins; vitamin preparations, namely, vitamin supplements; medical preparations for slimming; mineral food supplements ] | SECTION 71 - CANCELLED | — |
| 041 | [ Arranging and conducting of educational colloquiums, conferences, seminars and events for scientific purposes in the field of microbiota, of probiotics as pharmaceutical preparations, of the probiotics industry, of good practice in the field of microbiota, of probiotics, of changes to regulations relating to probiotics and microbiota ] | SECTION 71 - CANCELLED | — |
| 042 | Laboratory services for the provision of scientific analysis and research services, medical, pharmaceutical, pharmacological, bacteriological, chemical and microbiological, design and production of pharmaceutical preparations, probiotics, tribiotics for others; consulting in production of pharmaceutical preparations; quality control; testing in laboratory; services for assessing the efficiency of pharmaceuticals; auditing and auditing pharmaceutical manufacturing processes; packaging design services; kitchen design of preventive quality assurance and quality control relating to the manufacture of pharmaceutical preparations; auditing and testing standards and practices in the field of the manufacture of probiotics, tribiotics, ensure compliance with governmental regulations and industrial practices, practices quality control and quality assurance; conducting pharmaceutical research projects and technical project studies; engineering; provision of information and data relating to medical and scientific research in the field of pharmaceuticals, probiotics, and clinical trials relating to scientific research and development; provision and exchange of knowledge, industrial know-how and data relating to scientific research and development; provision and exchange of information and data exchange between scientists, manufacturers and health authorities relating to pharmaceutical regulatory affairs and the application thereof to probiotics; expertise services and technical advice in the field of scientific research for medical and pharmaceutical purposes, in the field of probiotics; development and maintenance of data banks and databases; extraction and retrieval of information and data mining; managing of working groups bringing together scientists and manufacturers to resolve problems in connection with probiotics; research and drafting of information provided by scientific research in the field of medical research, pharmaceutical, pharmacological in regulatory affairs in the field of probiotics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOSE
- Other trademarks owned by BIOSE
- Other trademarks owned by BIOSE INDUSTRIE
- Other trademarks owned by BIOSE
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named BIOSE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 16, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Aug 16, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Aug 10, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 5, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jan 22, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 11, 2025 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jul 24, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 31, 2023 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 23, 2023 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 23, 2023 | INPC | INVALIDATION PROCESSED | — |
| Sep 13, 2023 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 13, 2023 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jan 13, 2023 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Jan 10, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 1, 2022 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Sep 11, 2020 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Mar 13, 2017 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Mar 3, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 17, 2017 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Feb 13, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 13, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 11, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 11, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 26, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 6, 2016 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 20, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 16, 2016 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 14, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 2, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 2, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 27, 2016 | ALIE | ASSIGNED TO LIE | — |
| May 17, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 26, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 4, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 4, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 4, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 3, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 25, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 25, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2016 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Feb 23, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |